Navigation Links
Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model
Date:3/23/2017

SEATTLE, March 23, 2017 /PRNewswire/ -- Kineta, Inc., a biotechnology company focused on the translational development of novel therapies in immuno-oncology, today announced the discovery and characterization of several "hit to lead" small molecule compounds that activate interferon response factor 3 (IRF3) via RIG-I like receptor (RLR) pathways and demonstrate immune-mediated tumor regression in a murine colon carcinoma mouse model.  Furthermore, mice in the study who demonstrated complete tumor regression to initial drug treatment were resistant to tumor re-challenge confirming an adaptive immune response in these animals.  The findings were presented on March 22nd at the Keystone Symposia on Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology conference.

"Tumors exist in an immuno-suppressive environment and have many strategies of immune evasion.   Kineta's RLR agonists redirect the immune system to break tumor tolerance and elicit novel antigen-specific T-cell responses", said Shawn Iadonato, CEO of Kineta.  "These data are groundbreaking in cancer immuno-therapy as we successfully established tumor immunity in mice that had complete regression to an initial tumor."

In this study, Kineta's novel small molecule compounds demonstrated two immunomodulatory activities.  First, they stimulate the RLR/IRF3 pathway in myeloid cells to induce the secretion of inflammatory chemokines/cytokines by human peripheral blood mononuclear cells and dendritic cells.  Second, they induce immunogenic cell death in the CT26 colon carcinoma model.  Inducing ICD in tumor cells results in the release of danger signals including ATP, HMGB1, and calreticulin that ultimately enhance immune recognition of the tumor. 

"When ICD is elicited in tumor cells, they activate 'kill-me' markers such as ATP, HMGB1 and calreticulin.  The immune system recognizes these markers and initiates an anti-tumor response", said Kristin Bedard, VP Research and Development at Kineta.  "In turning a cold tumor hot, we believe that Kineta's RLR agonists can work in synergy with other immuno-therapies like checkpoint inhibitors to potentially enhance efficacy and patient survival."

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs.  For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta's plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy
151837@email4pr.com 
(206) 378-0400

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kineta-rlr-agonist-demonstrates-tumor-regression-and-an-adaptive-immune-response-in-colon-carcinoma-model-300428378.html


'/>"/>
SOURCE Kineta, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco
2. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
3. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
4. Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting
5. Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors
6. Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for Nelotanserin, a Novel Inverse Agonist of the 5-HT2A Receptor
7. Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes
8. Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs into Clinical Development
9. Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
10. Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohns and Colitis Organization (ECCO) Congress
11. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... 2017 , ... Stratevi, a boutique firm that partners with healthcare companies to ... an office in downtown Boston at 745 Atlantic Ave. , “We are seeing ... evidence on the value they provide, not just to patients, but also payers. Having ...
(Date:5/22/2017)... , ... May 22, 2017 , ... ... that it is exhibiting in booth B2 at the Association for Pathology ... 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is ... trial and error process by finding the right antidepressant faster. CNSDose speeds ... doctor-patient relationship through a personalized approach to treatment. , A peer-reviewed ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science ... technologies ripe for commercialization, and who are affiliated with the 21 partner academic ... proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept program ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):